Enanta Pharma第一季度每股收益$(1.05)好于预期$(1.35),销售额$1696万低于预期$1725万

财报速递2025-02-11
Enanta Pharma (NASDAQ:ENTA)报告季度每股亏损$(1.05),好于分析师共识预期的$(1.35),超出22.22%。与去年同期每股亏损$(1.58)相比,这是一个33.54%的增幅。公司报告季度销售额为1696万美元,低于分析师共识预期的1725万美元,差距为1.68%。与去年同期的1800万美元相比,这是一个5.80%的下降。

以上内容来自Benzinga Earnings专栏,原文如下:

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.35) by 22.22 percent. This is a 33.54 percent increase over losses of $(1.58) per share from the same period last year. The company reported quarterly sales of $16.96 million which missed the analyst consensus estimate of $17.25 million by 1.68 percent. This is a 5.80 percent decrease over sales of $18.00 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法